ARNA Related Analyst Ratings
-
Needham Sees Strong Start for Arena's (ARNA) Belviq in U.S.; European Approval Unlikely
-
VIVUS (VVUS) Cuts Qsymia Price by About 70%; Arena (ARNA) on Watch
-
Arena (ARNA) Will Need Lower Co-Payments, Broader Coverage for Belviq Success (VVUS)
-
Leerink Swann Resumes Arena Pharma (ARNA) at Outperform
-
VIVUS, Inc. (VVUS) Qsymia Prescriptions Show Gains During Slow Holiday Week (ARNA) (OREX)
-
Brean Capital Downgrades Vivus (VVUS) to Sell, Low Qsymia Coverage Means Low Sales
-
JPMorgan Confident Orexigen's (OREX) Will Receive FDA Approval; Comments on Meeting
-
Orexigen (OREX) Slumps as Many Expected 'Better News' for Contrave
-
VIVUS (VVUS) Qsymia Prescriptions Pop Following Thanksgiving Glut (ARNA) (OREX)
-
Jefferies Remains Bullish on Arena Pharma (ARNA) But Tempers Valuation Target on Data from Rival
-
Latest Qsymia Data Shapes Up Potential Bear Case for VIVUS (VVUS) and Peers (ARNA) (OREX)
-
VIVUS (VVUS) Qsymia Prescriptions Remain High Amid Birth Defect Warning; Positive for Arena (ARNA)
-
VIVUS (VVUS) Qsymia Continues to See Strong Early Demand
-
VIVUS' (VVUS) Qsymia Prescription Insurer Pay Rate Rose 5% in Week Two
-
Not Expecting E.U. Approval for Vivus' (VVUS) Qsiva, Could be a Plus for Orexigen (OREX) - Analyst
-
Orexigen (OREX) Surges On 'Aggressive' Buy Calls Ahead of Catalysts
-
Credit Suisse Starts Arena Pharma (ARNA) at Underperform
-
VIVUS' (VVUS) Qsymia Approved and has Advantages Over Belviq
-
Brean Murray Positive on Vivus (VVUS) after Approval
-
VIVUS (VVUS) Gets a Boost from Uber-Bullish Orexigen (OREX) Call
-
With Plenty of Good Arguments for Both Bulls and Bears, VIVUS (VVUS) Qnexa Approval at 50/50 - Jefferies
-
UPDATE: JPMorgan Upgrades Orexigen Therapeutics (OREX) to Overweight, Best Opportunity in Obesity Space
-
JPMorgan Boosts Target on Vivus (VVUS), More Confidence in Approval
-
JPMorgan Muted on Arena Pharma (ARNA) After Approval, Lifts Target to $11
-
Canaccord Genuity Morning Coffee on Arena Pharma. (ARNA): Does This Mean I Can Keep Eating Super-Sized Double Big Mac Meals?
-
Needham & Company on Arena Pharma (ARNA); Obese Population Large, But Poor Track Record of Drugs in the Space
-
Jefferies Boosts Arena (ARNA) Target to $20
-
BMO Capital Downgrades Arena Pharma (ARNA) to Market Perform Ahead of PDUFA
-
Jefferies Sees a 3-6 Month Delay for Arena's (ARNA) Lorcaserin But Reiterates Buy Rating
-
Leerink Still Sees VIVUS's (VVUS) Qnexa as 'Obesity Therapy of Choice'
-
Piper Jaffray Upgrades Arena Pharma (ARNA) to Overweight
-
Needham Maintains Cautious View of Arena Pharma (ARNA)
-
Leerink Swann Upgrades Arena Pharma (ARNA) to Outperform; Positive Panel Vote For Lorcaserin
-
Jefferies Upgrades Arena Pharma (ARNA) to Buy
-
BMO Capital Upgrades Arena Pharma (ARNA) to Outperform, Raises Target 600%
-
Vivus (VVUS) Qnexa PDUFA Delay a "Minor Hiccup" - Leerink Swann
-
Arena (ARNA) Shares Sink as Piper Jaffray Downgrade Weighs
-
Piper Jaffray Cuts Arena Pharma (ARNA) to Neutral
-
Jefferies Keeps Lowest Rating on Arena Pharma (ARNA) After Q4 Call and Into May Lorcaserin Panel
-
Editorial Suggests Possible Pre-Approval CV Testing For VIVUS' (VVUS) Qnexa, Others - Analyst
-
Leerink Swann: Buyers of Orexigen Therapeutics (OREX) Into Next Panel; Preferred Small/Midcap Biotech Pick
-
Needham & Company Maintains a 'Hold' on Arena Pharma (ARNA); Meaningful Risks to Lorcaserin Approval
-
Needham & Company Remains Cautious on Arena Pharma (ARNA) Given Lingering Uncertainty Around Rat Mammary Tumors; Lorcaserin NDA Resubmitted
-
Piper Jaffray Upgrades Arena Pharma (ARNA) to Overweight
-
Needham & Company Maintains a 'Hold' on Arena Pharma (ARNA); Remain Cautious on the Stock
-
BMO Starts Biotech Stocks: AMGN, HGSI, REGN, CELG at Outperform, AMLN, GILD, ARNA at Market Perform, BIIB at Underperform
-
Barclays Maintains an 'Underweight' on Arena Pharma (ARNA); Reports 4Q, Uncertainty Persists
-
Summer Street Upgrades Arena Pharma (ARNA) to Neutral; Some Clarity From This Week’s FDA Meeting
-
UBS Maintains a 'Neutral' on Arena Pharma (ARNA); BLOOM-DM: Likely Not Enough
-
Canaccord Genuity reiterates a 'Hold' on Arena Pharmaceuticals (ARNA); Lorcaserin CR Provides Only Very Dim Light At The End of Long Tunnel
Back to ARNA Stock Lookup
